244 related articles for article (PubMed ID: 17184146)
1. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Anderlová K; Dolezalová R; Housová J; Bosanská L; Haluzíková D; Kremen J; Skrha J; Haluzík M
Physiol Res; 2007; 56(5):579-586. PubMed ID: 17184146
[TBL] [Abstract][Full Text] [Related]
2. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
Haluzík MM; Anderlová K; Doležalová R; Adamíková A; Haluzíková D; Housová J; Svacina S; Haluzík M
Physiol Res; 2009; 58(1):93-99. PubMed ID: 18198986
[TBL] [Abstract][Full Text] [Related]
3. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
[TBL] [Abstract][Full Text] [Related]
4. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
[TBL] [Abstract][Full Text] [Related]
5. Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment.
Kavalkova P; Touskova V; Roubicek T; Trachta P; Urbanova M; Drapalova J; Haluzikova D; Mraz M; Novak D; Matoulek M; Lacinova Z; Haluzik M
Horm Metab Res; 2013 Oct; 45(11):820-6. PubMed ID: 23979788
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
7. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Otto C; Otto B; Frost RJ; Vogeser M; Pfeiffer AF; Spranger J; Parhofer KG
Acta Diabetol; 2007 Jun; 44(2):65-8. PubMed ID: 17530469
[TBL] [Abstract][Full Text] [Related]
8. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Doležalová R; Haluzík MM; Bošanská L; Lacinová Z; Kasalová Z; Stulc T; Haluzík M
Physiol Res; 2007; 56(6):741-748. PubMed ID: 17087601
[TBL] [Abstract][Full Text] [Related]
9. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
[TBL] [Abstract][Full Text] [Related]
10. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Seber S; Ucak S; Basat O; Altuntas Y
Diabetes Res Clin Pract; 2006 Jan; 71(1):52-8. PubMed ID: 16009445
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.
Wu H; Wei L; Bao Y; Lu J; Huang P; Liu Y; Jia W; Xiang K
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E628-34. PubMed ID: 19088257
[TBL] [Abstract][Full Text] [Related]
12. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
14. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
[TBL] [Abstract][Full Text] [Related]
15. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
16. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
17. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
Tan CE; Chew LS; Tai ES; Chio LF; Lim HS; Loh LM; Shepherd J
Atherosclerosis; 2001 Feb; 154(2):469-74. PubMed ID: 11166781
[TBL] [Abstract][Full Text] [Related]
18. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
19. Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes.
Lu HL; Wang HW; Wen Y; Zhang MX; Lin HH
World J Gastroenterol; 2006 Mar; 12(11):1747-51. PubMed ID: 16586545
[TBL] [Abstract][Full Text] [Related]
20. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients.
Hansen D; Dendale P; Beelen M; Jonkers RA; Mullens A; Corluy L; Meeusen R; van Loon LJ
Eur J Appl Physiol; 2010 Jun; 109(3):397-404. PubMed ID: 20131064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
